Considerations in selecting rapid-onset opioids for the management of breakthrough pain
Michael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the i...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-06-01
|
Series: | Journal of Pain Research |
Online Access: | http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254 |
id |
doaj-22e4a7c2cb4e4f37848a2a84d49c1245 |
---|---|
record_format |
Article |
spelling |
doaj-22e4a7c2cb4e4f37848a2a84d49c12452020-11-25T00:09:31ZengDove Medical PressJournal of Pain Research1178-70902013-06-012013default435436Considerations in selecting rapid-onset opioids for the management of breakthrough painPerelman MLeake SMichael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the identification by Farrar et al2 of a 33% (often ≥2 point) change in the pain intensity difference as a measure of a ‘clinically important improvement’. For these reasons, Smith focuses on the various transmucosal fentanyl formulations that offer a rapid onset and he provides a nice summary of the key features of each of the available products.View original paper by Howard S Smith.http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Perelman M Leake S |
spellingShingle |
Perelman M Leake S Considerations in selecting rapid-onset opioids for the management of breakthrough pain Journal of Pain Research |
author_facet |
Perelman M Leake S |
author_sort |
Perelman M |
title |
Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
title_short |
Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
title_full |
Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
title_fullStr |
Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
title_full_unstemmed |
Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
title_sort |
considerations in selecting rapid-onset opioids for the management of breakthrough pain |
publisher |
Dove Medical Press |
series |
Journal of Pain Research |
issn |
1178-7090 |
publishDate |
2013-06-01 |
description |
Michael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the identification by Farrar et al2 of a 33% (often ≥2 point) change in the pain intensity difference as a measure of a ‘clinically important improvement’. For these reasons, Smith focuses on the various transmucosal fentanyl formulations that offer a rapid onset and he provides a nice summary of the key features of each of the available products.View original paper by Howard S Smith. |
url |
http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254 |
work_keys_str_mv |
AT perelmanm considerationsinselectingrapidonsetopioidsforthemanagementofbreakthroughpain AT leakes considerationsinselectingrapidonsetopioidsforthemanagementofbreakthroughpain |
_version_ |
1725411517326688256 |